GHRP: Growth Hormone Secretagogues Explained
By Charles Kamen, MD, board-certified neurologist
CJC-1295 and Ipamorelin are growth-hormone-releasing peptides that prompt your own pituitary gland to secrete more growth hormone through two complementary pathways — CJC-1295 acting as a long-acting GHRH analog and Ipamorelin through the ghrelin receptor. Together they form one of the most common combination protocols for supporting sleep, recovery, and lean body composition.[1][2]
Dr. Charles Kamen, MD, a board-certified neurologist at LiveNow Longevity in Las Vegas, uses these peptides inside a supervised, monitored peptide therapy program — never as a standalone shortcut. Individual results vary.
What Are CJC-1295 and Ipamorelin?
They are growth hormone secretagogues — compounds that stimulate the pituitary gland to produce and release more of your own growth hormone. CJC-1295 is a GHRH analog with a notably long half-life, because it binds to albumin in the bloodstream and resists rapid breakdown.[1]
Ipamorelin is a selective growth hormone secretagogue that triggers release through a different route — the ghrelin receptor — and is valued for producing fewer side effects than older, non-selective secretagogues. Because each peptide acts on a separate pathway, they are typically prescribed together rather than alone.[2]
How Do CJC-1295 and Ipamorelin Work Together?
They act synergistically: CJC-1295 stimulates the pituitary directly as a GHRH analog, while Ipamorelin adds a second signal through the ghrelin pathway — and a growth-hormone-releasing peptide combined with GHRH releases more growth hormone than either does alone.[3]
This two-pathway approach aims to restore a more natural, pulsatile pattern of growth hormone release rather than the flat, oversized surge of injected growth hormone — usually a smoother rise with fewer side effects.
What Benefits Do Patients Report?
The benefits patients describe most map onto growth hormone's core roles — better sleep, faster recovery, more energy, and a gradual shift toward lean tissue over fat. Growth hormone is released mainly during deep sleep, which is one reason improved sleep quality is often the very first change people notice.
Commonly reported benefits include:
- Better sleep — deeper, more consolidated sleep, often the earliest reported change
- Faster recovery from exercise, training, and injury
- More muscle, less fat — a gradual improvement in body composition toward lean tissue
- More energy and reduced daytime fatigue
- Support for skin elasticity and tissue repair
- Improved mood and cognitive sharpness reported by some patients
Evidence Base
Research supports growth-hormone-releasing peptide benefits across several populations. A randomized controlled trial in healthy older adults found that an oral ghrelin mimetic improved body composition and raised IGF-1, a key marker of growth hormone activity.[4]
Still, responses vary with age, baseline health, sleep, diet, and training — which is why outcomes are tracked with labs rather than assumed.
How Are CJC-1295 and Ipamorelin Dosed?
They are given as a small subcutaneous injection, with common protocols using 3-5 injections per week, often timed at night to align with the body's natural overnight growth hormone pulse.[5]
Dr. Kamen sets dosing from your goals, health status, and response — starting conservatively and titrating gradually based on tolerance and follow-up IGF-1 levels. As a neurologist, he pays particular attention to sleep quality and daytime energy as early signals that the protocol is working.
Are CJC-1295 and Ipamorelin Safe, and Who Should Be Cautious?
Under physician supervision they are generally well tolerated, with side effects that are usually mild and dose-dependent — water retention, temporary numbness or tingling, and appetite changes are the most commonly reported. Because growth hormone can drive the growth of existing cells, these peptides are not appropriate for everyone.
Current evidence does not link growth-hormone-releasing peptides to causing cancer, but growth hormone can accelerate the growth of existing cancer cells — so cancer screening before starting therapy is standard at the Las Vegas clinic, along with ongoing IGF-1 monitoring throughout treatment.
Key Takeaways
- CJC-1295 raises growth hormone through the GHRH pathway; Ipamorelin works through the ghrelin receptor.
- Used together, the two peptides act synergistically to elevate your own growth hormone.
- Most-reported benefits are better sleep, faster recovery, more energy, and improved lean body composition.
- A randomized controlled trial in older adults found a ghrelin mimetic improved body composition and IGF-1.
- Standard administration is a subcutaneous injection, typically 3-5 times per week.
- Dr. Kamen screens for cancer before starting and monitors IGF-1 and clinical response throughout therapy.
Common Questions
Is CJC-1295/Ipamorelin the same as HGH injections?
No. These peptides prompt your own pituitary to release growth hormone in a more natural, pulsatile pattern. HGH injections deliver growth hormone directly from outside the body. The peptide approach aims for a smoother, more physiological rise with fewer side effects.
How soon will I notice results?
Most patients notice improved sleep within the first few weeks, since growth hormone is released mainly during deep sleep. Recovery, energy, and body-composition changes typically build over two to three months of consistent therapy. Individual responses vary with age, health, and lifestyle.
Can CJC-1295 and Ipamorelin help me build muscle?
They support a gradual shift toward lean tissue rather than dramatic overnight muscle gain. Pairing the peptides with resistance training and adequate protein optimizes body-composition results, because growth hormone and IGF-1 aid recovery and tissue repair. The peptides assist the work; they do not replace it.
What are the side effects?
Reported side effects are usually mild and dose-dependent, including water retention, temporary numbness or tingling, and appetite changes. Dr. Kamen starts with conservative doses, titrates gradually, and monitors for adverse effects, adjusting the protocol based on how you tolerate and respond to therapy.
Can I use these peptides while exercising?
Yes, and it is encouraged. Combining peptide therapy with resistance training and sufficient protein enhances the muscle-supporting and recovery benefits. Exercise itself stimulates natural growth hormone release, and the peptides complement that response, making consistent training and nutrition an important part of the protocol.
Do CJC-1295 and Ipamorelin cause cancer?
Current evidence does not link growth-hormone-releasing peptides to causing cancer. However, growth hormone can accelerate the growth of existing cancer cells, so cancer screening before starting therapy is standard at our Las Vegas clinic, followed by ongoing IGF-1 and clinical monitoring throughout treatment.
CJC-1295 and Ipamorelin offer a physician-supervised, monitored way to support your own growth hormone — for better sleep, recovery, and body composition, not a shortcut around them. Schedule a consultation with Dr. Kamen to determine whether this peptide protocol is appropriate for your health and longevity goals.
References
- Sackmann-Sala L, Ding J, Frohman LA, et al. Growth Horm IGF Res. 2009;19(6):471-477. (Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog).
- Raun K, et al. Eur J Endocrinol. 1998;139(5):552-561. (Ipamorelin, the first selective growth hormone secretagogue).
- Bowers CY, et al. J Clin Endocrinol Metab. 1990;70(4):975-982. (GH-releasing peptide stimulates GH release in normal men and acts synergistically with GHRH).
- Nass R, et al. Ann Intern Med. 2008;149(9):601-611. (Oral ghrelin mimetic improves body composition and IGF-1 in healthy older adults, RCT).
- Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006;91(12):4792-4797. (Pulsatile GH secretion during continuous stimulation by CJC-1295).
Wondering what’s right for you?
Get a straight answer from board-certified neurologist Dr. Charles Kamen, MD. The evaluation is $88 and is applied toward your protocol if you continue care.